Meinian Onehealth Plans Framework Cooperation Agreement with MEGA GENOMICS

Stock News11-06

Meinian Onehealth Healthcare Holdings Co.,Ltd. (002044.SZ) has announced that, based on its operational needs, it intends to sign a Framework Cooperation Agreement with MEGA GENOMICS (06667.HK).

Under the agreement, the company and its subsidiaries will collaborate with MEGA GENOMICS and its affiliates on testing services, as well as related supporting products required for testing and services, during the agreement's validity period. Both parties may, through mutual consultation and written agreement, add, adjust, or cancel specific cooperation projects based on market demand, business development, regulatory policies, and their respective operating conditions.

The signing of the Framework Cooperation Agreement with MEGA GENOMICS is necessary for daily operations and is conducive to leveraging business synergies between the two parties, stabilizing the supply of testing services and consumables, aligning with the company's development strategy, and helping to enhance the company's core competitiveness, profitability, and sustainable development capabilities.

Transaction prices will be determined fairly and reasonably based on market prices, and there is no circumstance that would harm the interests of the company and its shareholders, especially minority shareholders. It will not affect the company's independence, nor will it create dependence on related parties. It is not expected to have a significant adverse impact on the company's current and future financial condition or operating results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment